Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

"http://www.avidbio.com" target="_new">http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... consumers, are increasingly searching for food alternatives that ... nutritional benefits. The food ingredient market has numerous ... players such as Vital Force Technology (VFT). ... more than 4,000 energetic patterns, all tested to ...
(Date:7/31/2014)... 2014 Nearly 20,000 medical professionals and healthcare ... & Clinical Lab Expo in Chicago ... in diagnostic research and technology that will advance medicine ... As of Wednesday, July 30, more than 19,500 attendees ... Clinical Lab Expo, with more than 10,000 of these ...
(Date:7/31/2014)... ability to see through organs and even the entire ... as fine-grained cellular structures has been a long-time dream ... Press July 31st in the journal Cell ... methods for making opaque organs, bodies, and human tissue ... intact. The protocols could pave the way for a ...
(Date:7/31/2014)... SPRINGS, Colo. , July 31, 2014 /PRNewswire-USNewswire/ ... Grant awardee today with $25,000 to fund a ... Foundation,s inception in 2011, the gift was presented ... th Annual Meeting in Colorado ... who specialize in neurointerventional approaches to neurovascular conditions, ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... DirectorFAIRFAX, Va., Feb. 25 Edmond Scientific Company ... our team of Tony Mallia as Practice Director. ... bringing to bear his experience of enterprise integration in ... financial services sectors. The core goal of this methodology ...
... plastic surgeryMEDFORD, Mass., Feb. 25 Serica ... developing silk-based biomaterial platforms for tissue regeneration, ... from the U.S. Food and Drug Administration ... long term bioresorbable scaffold technology."We are delighted ...
... 25 Bio-Matrix Scientific Group,Inc. (OTC Bulletin Board: BMSN) ... created positions on its management team. Feng Lin, M.D., ... Laboratory/Scientific,Director and Marilyn Panahi is serving as Quality Assurance ... and Marilyn Panahi bring tremendous expertise to the,administrative operations ...
Cached Biology Technology:Edmond Scientific Company 'Spotlight on the Executive': 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 2Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 3Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair 4Bio-Matrix Scientific Group Announces New Hires to Management Team 2
(Date:8/1/2014)... enormous opportunities for both biological and future clinical ... cells in the body, offering immense hope of ... kidney, liver and lung diseases and making damaged ... Prof. Jinhui Chen from Indiana University in USA ... myriad biological, ethical, legal, political, and financial challenges. ...
(Date:8/1/2014)... Colo., USA One of the most diverse families ... as Lucinidae (or lucinids) -- originated more than 400 ... and life habits like those of its modern members. ... the University of Hawaii, published online on 25 July ... through significant symbiotic relationships. , At is origin, the ...
(Date:8/1/2014)... -- LiveScan Service Provider Binary Biometrics is pleased to welcome Kevin ... will improve its mobile service capabilities and add more daily appointments, which will ... service several new cities such as, but not limited to, Daytona ... Deltona , Edgewater , Holly ... Beach , Oak Hill , Orange City ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3
... great at protecting leaves from being chomped by slugs, suggests ... . Although they lurk in the soil, they seem to ... the amount of damage slugs do to individual plants. ... 100 worst alien species in Europe and are considered a ...
... more than 13,000 men identified four new genetic variants ... most commonly diagnosed type in young men today. The ... 12 in Nature Genetics by researchers at ... of Pennsylvania . The discovery of these genetic ...
... anomalous pulmonary venous connection (TAPVC), one type of "blue ... occurs when pulmonary veins don,t connect normally to the ... oxygenated blood throughout the body, and TAPVC babies are ... , TAPVC is usually detected in newborns when babies ...
Cached Biology News:Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 2Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 3Mutation causing wrong-way plumbing explains 1 type of blue-baby syndrome 2
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
Biology Products: